Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?

PURPOSE OF REVIEW: Therapeutic alternatives to treat metastatic renal cell carcinoma (mRCC) are increasing, and combination therapies, including antiangiogenic agents and tyrosine kinase/mTOR/immune checkpoint inhibitors, are identified as the gold standard driven by the results of recent clinical s...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Ernesto, Bersanelli, Melissa, Gelibter, Alain Jonathan, Borsellino, Nicolò, Caserta, Claudia, Doni, Laura, Maruzzo, Marco, Mosca, Alessandra, Pisano, Carmela, Verzoni, Elena, Zucali, Paolo Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575734/
https://www.ncbi.nlm.nih.gov/pubmed/34748099
http://dx.doi.org/10.1007/s11912-021-01140-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575734/
https://www.ncbi.nlm.nih.gov/pubmed/34748099
http://dx.doi.org/10.1007/s11912-021-01140-9

Ejemplares similares